Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its pipeline candidate EMB-06, a BCMAxCD3 bispecific antibody (BsAb), at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in California. The late-breaker poster presentation will detail initial safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data from the Phase I dose escalation stage of a Phase I/II study in patients with relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).
EMB-06 Development and Platform
Developed on EpimAb’s proprietary CD3 panel and bispecific platforms, EMB-06 is an innovative 2+2 BCMA×CD3 T-cell engaging BsAb. EpimAb has stated that this BsAb has demonstrated lower levels of cytokine release in both preclinical and clinical studies, marking a significant advancement in the field of immunotherapy.
Initial Data and Platform Capabilities
The initial data from the study is viewed by the Shanghai firm as indicative of its BsAb platform and CD3 panel capabilities. These capabilities enable the targeting of tumor antigens while reducing the risk of cytokine release and neurotoxicity, which are critical considerations in the development of effective and safe immunotherapies.-Fineline Info & Tech
